Ventyx Biosciences

Phase 2 trial of VTX958, an oral TYK2 inhibitor, demonstrated significant endoscopic improvement in Crohn's disease patients, with up to 32.4% achieving endoscopic response at Week 12.

Ventyx Biosciences presented extended Phase 2 trial results for tamuzimod (VTX002) at UEG Week 2024, demonstrating sustained efficacy in ulcerative colitis treatment over 52 weeks.

Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.

• The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions. • NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH. • Clinical trials are underway, with companies like Novo Nordisk and NodThera reporting positive data on their NLRP3 inhibitor candidates. • Collaborations, such as the one between Halia Therapeutics and Biolexis Therapeutics, are advancing the development of brain-penetrant NLRP3 inhibitors for neuroinflammation.

Ventyx Biosciences advances VTX3232 into Phase 2 trials for early Parkinson's and obesity, expecting topline results in H1 and H2 2025, respectively.

Ventyx Biosciences presented 52-week data from its Phase 2 trial of tamuzimod (VTX002) in ulcerative colitis at UEG Week 2024, showcasing sustained efficacy.

Ventyx Biosciences has commenced a Phase 2a clinical trial of VTX3232 in patients with early Parkinson's disease, marking a significant step in neuroinflammatory disease treatment.